University of Edinburgh at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

University of Edinburgh brings 2 presentations to ENA 2026 in Barcelona. Its program centres on proximity inducers beyond current PROTACs and on drug combinations in lung cancer. It reports that NXP900, a first-in-class switch-control SRC/YES1 inhibitor, works in strong synergy with KRAS inhibitors in drug-sensitive and resistant NSCLC models, both in cells and in animals.

Organization	ENA 2026 Attendance
University of Edinburgh Edinburgh, UK
ed.ac.uk Universities & institutes Research university in Scotland whose Institute of Genetics and Cancer runs cancer research.	Session Fri Nov 20 9:30–10:45am Workshop 8: Proximity inducers beyond current PROTACs Drug design Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies First-in-class switch-control SRC/YES1 inhibitor NXP900 demonstrates potent synergy with KRAS inhibitors in drug-sensitive and resistant NSCLC models in vitro and in vivo Targeted agents

Instantly find 20 buyers from University of Edinburgh

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction